EyeGene Inc. (KOSDAQ:185490)

EyeGene Statistics

Total Valuation

EyeGene has a market cap or net worth of KRW 75.14 billion. The enterprise value is 50.06 billion.

Market Cap	75.14B
Enterprise Value	50.06B

Important Dates

The last earnings date was Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

EyeGene has 27.03 million shares outstanding. The number of shares has increased by 10.63% in one year.

Current Share Class	27.03M
Shares Outstanding	27.03M
Shares Change (YoY)	+10.63%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.59%
Owned by Institutions (%)	n/a
Float	19.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.95
PB Ratio	1.59
P/TBV Ratio	1.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.37
EV / Sales	12.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.63

Financial Position

The company has a current ratio of 3.34, with a Debt / Equity ratio of 0.05.

Current Ratio	3.34
Quick Ratio	3.20
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.39
Interest Coverage	-15.03

Financial Efficiency

Return on equity (ROE) is -22.60% and return on invested capital (ROIC) is -12.40%.

Return on Equity (ROE)	-22.60%
Return on Assets (ROA)	-10.49%
Return on Invested Capital (ROIC)	-12.40%
Return on Capital Employed (ROCE)	-21.41%
Revenue Per Employee	84.38M
Profits Per Employee	-243.68M
Employee Count	47
Asset Turnover	0.06
Inventory Turnover	4.22

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.16% in the last 52 weeks. The beta is 1.42, so EyeGene's price volatility has been higher than the market average.

Beta (5Y)	1.42
52-Week Price Change	-14.16%
50-Day Moving Average	3,108.10
200-Day Moving Average	2,968.43
Relative Strength Index (RSI)	39.15
Average Volume (20 Days)	60,943

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EyeGene had revenue of KRW 3.97 billion and -11.45 billion in losses. Loss per share was -423.84.

Revenue	3.97B
Gross Profit	1.17B
Operating Income	-10.92B
Pretax Income	-11.73B
Net Income	-11.45B
EBITDA	-8.63B
EBIT	-10.92B
Loss Per Share	-423.84

Balance Sheet

The company has 29.75 billion in cash and 2.57 billion in debt, giving a net cash position of 27.19 billion or 1,005.87 per share.

Cash & Cash Equivalents	29.75B
Total Debt	2.57B
Net Cash	27.19B
Net Cash Per Share	1,005.87
Equity (Book Value)	47.29B
Book Value Per Share	1,671.53
Working Capital	22.42B

Cash Flow

In the last 12 months, operating cash flow was -5.88 billion and capital expenditures -678.29 million, giving a free cash flow of -6.56 billion.

Operating Cash Flow	-5.88B
Capital Expenditures	-678.29M
Free Cash Flow	-6.56B
FCF Per Share	-242.58

Margins

Gross margin is 29.52%, with operating and profit margins of -275.40% and -288.77%.

Gross Margin	29.52%
Operating Margin	-275.40%
Pretax Margin	-295.74%
Profit Margin	-288.77%
EBITDA Margin	-217.72%
EBIT Margin	-275.40%
FCF Margin	n/a

Dividends & Yields

EyeGene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.63%
Shareholder Yield	n/a
Earnings Yield	-15.24%
FCF Yield	-8.73%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.

Last Split Date	Jun 28, 2021
Split Type	Forward
Split Ratio	1.2

Scores

EyeGene has an Altman Z-Score of -0.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.27
Piotroski F-Score	2